Evaluate maintains detailed, comprehensive coverage of over 90,000 marketed and R&D products. Our coverage includes proprietary classifications such as NME, NDA, Generic, Orphan, OTC, and more. There are over 300 sales fields per product with Worldwide, USA, Europe, Japan, Quarterly, Half-
Key data highlights
Product summary page
In this page
From a product summary page, you can access high-
Each product will have a Product Detail Summary which takes an in-
Product related FAQs
Does Evaluate cover Generics?
Evaluate does not cover all generic products. The product portfolio only covers the commercially significant generics for a company (those that disclose sales data for which specific information is disclosed by the company). Therefore sales data for generic products is available in Evaluate, but it is not as comprehensive as it is for branded products
How does Evaluate tag Phase I/II or Phase II/III products?
We primarily source our phase of development information of a product from 2 types of sources:
What is the methodology behind classifying drugs as "suspended" or "abandoned"?
A product is listed as “suspended” when a company announces that they have paused the development of a product. A product can be listed as “Abandoned” using 3 different methods: